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Abstract
Background: Intra-peritoneal (i.p.) chemotherapy is an encouraging treatment option for ovarian
cancer with peritoneum involvement in addition with intravenous (i.v.) chemotherapy. Intra-
operative i.p. chemotherapy is an interesting method of administration by enhancing the diffusion
of chemotherapy. This study had assessed the feasibility of intra-operative i.p. chemotherapy in
patients with peritoneal carcinoma of ovarian cancer.
Methods: From January 2003 to February 2006, 47 patients with stage III ovarian cancer were
treated with standard paclitaxel carboplatin intravenous chemotherapy and debulking surgery with
intra-operative i.p. chemotherapy. After optimal cytoreductive surgery, defined by no unresectable
residual disease > 1 cm, i.p. chemotherapy was performed during surgery. The peritoneal cavity
was filled by 3 litres of isotonic saline pre-heated at 37 degrees and 90 mg of cisplatin. The sequence
was repeated twice during 2 hours based on previous published studies which optimized the
cisplatin dosage and exposure duration. Optimal diffusion was obtained by stirring by hands during
the 2 hours.
Results: Median age was 59.6 years. No severe haematological or non-haematological toxicity
induced by intra operative i.p. chemotherapy was reported. No patient died due to the
complications of surgery or the i.p. chemotherapy. No neurotoxicity occurred, and one patients
had renal impairment.
Conclusion: This study demonstrates the feasibility of intra-operative i.p. chemotherapy with
cisplatin after optimal resection of peritoneal tumor nodules. Further randomized trials are planned
to investigate the clinical benefit of this therapeutic modality.
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Background
Ovarian cancer is the leading cause of gynaecologic can-
cer-related death in most industrialized countries and the
fifth cause of cancer death among women [1-3]. Approxi-
mately 60% of women have an advanced FIGO stage III-
IV ovarian cancer at diagnosis and the 30% 5-year survival
rate is dramatically poor. The peritoneal cavity is the main
site of disease involvement in ovarian cancer [4,5]. Stand-
ards treatments include exploratory laparotomy with
cytoreductive surgery followed by intra-venous (i.v.) plat-
inum/taxane-based chemotherapy [6-8]. Nevertheless,
additional intra-peritoneal (i.p.) chemotherapy is an
encouraging treatment option for ovarian cancer with per-
itoneum involvement [9,10]. The rationale for i.p. chem-
otherapy is based on high drug concentration exposure in
the peritoneal cavity leading to an increased cytotoxicity
and avoiding a high level of systemic toxicity [11-16].
However, despite the advantage of a high concentration of
anticancer drugs, the results obtained with i.p. chemother-
apy are still debatable in terms of complete and lasting
responses [17]. One of the reasons suggested to explain
those failures was the difficulty for i.p. chemotherapy to
diffuse widely in the peritoneal cavity due to adhesion
and/or anatomic niches. Intra-operative i.p. chemother-
apy was suggested with the aim to improve its results
[18,19]. The administration of i.p. chemotherapy during
surgery allows an optimal peritoneal cavity exposure con-
trolled by the surgeon who stirs the cisplatin containing
solution by hand. The goal of this present report was to
analyze the feasibility and the toxicity of this method of
intra-operative i.p. chemotherapy.
Patients and methods
Between January 2003 and February 2006, 47 patients
with advanced epithelial ovarian cancer classified FIGO
stage IIIC were included and treated in our institution,
University Hospital of Besançon (France). In 31 patients,
treatment consisted in 4 cycles of induction i.v. chemo-
therapy with 175 mg paclitaxel per square meter of body
surface area (mg/m2) over 3 hours and area under the
(AUC) curve targeted to 5 for carboplatin over 30 minutes
on day 1, every 3 weeks. This chemotherapy was followed
by debulking surgery with intra operative i.p. chemother-
apy using cisplatin. Initial debulking surgery was per-
formed when complete tumoral resection seemed
feasible. In 31 cases this initial surgery seemed not possi-
ble and induction chemotherapy was administered. In 16
patients initial debulking surgery was performed and
appeared to be suboptimal with major residual lesions in
7 cases. In all cases, complementary systemic chemother-
apy with paclitaxel and carboplatin was administered.
This chemotherapy was followed by a second look surgery
with or without tumoral debulking and with the adminis-
tration of intraperitoneal chemotherapy if residual disease
was smaller than 10 mm. After debuloking surgery, 2 to 4
additional cycles of paclitaxel/carboplatin chemotherapy
were administered. In 16 patients, treatment included ini-
tial debulking surgery followed by 6 to 8 cycles of i.v. pacl-
itaxel/carboplatin chemotherapy. Then, second-look
surgery with intra-operative i.p. ciplatin chemotherapy
was performed. In all cases, an optimal cytoreductive sur-
gery, defined by no unresectable residual disease larger
than 10 mm, was achieved either at presentation or after
completion of induction chemotherapy. Intraoperative
i.p. chemotherapy was performed according to Royer et al
description using the optimization suggested by pharma-
cokinetics analysis [20,21]. These authors have identified
an optimal dose and duration of exposure of cisplatin for
intraperitoneal treatment based on pharmacokinetic –
pharmacodynamic studies. Previously, preclinical results
have identified the minimal doses and the optimal dura-
tion of platin exposure required to obtain maximal cyto-
toxic activity [22]. During surgery, after resection of all
residual disease, the peritoneal cavity was filled by 3 liters
of isotonic saline pre-heated at 37° and a total cisplatin
dose of 90 mg during 1 hour. The sequence was repeated
twice and the optimal distribution was obtained by stir-
ring by hand during the 2 hours. Then, the peritoneal cav-
ity was cleared out and rinsed before closing down.
Concomitant i.v. hydration with 3000 ml normal saline,
2.2 mM Ca2+ glucuronate, 1 g/l Mg2+, 2 g/l KCl and 3 g/l
NaCl was administered to prevent renal toxicity. The fol-
low up of the patients was performed every 12 weeks with
clinical examination, CA 125 test, abdominal and pelvic
ultrasound or CT scan.
Statistical analysis
All estimated confidence interval parameters were
designed with a significance level of α = 0.05. Time-to-
event endpoints of overall survival (OS), disease progres-
sion (DP) and response duration curves were evaluated
using Kaplan-Meier non-parametric methods [23] using
JMP® Software (SAS, Cary NC). The duration of DP is
defined as the time from the diagnosis to the date of pro-
gressive disease or death. The overall survival is defined as




Data were updated October 27, 2006. Table 1 summarizes
the characteristics of patients. A majority of patients
(66%) had initial chemotherapy followed by debulking
surgery. The median duration of surgery was 7 hours and
10 minutes (range: 5 hours 10 minutes to 9 hours and 30
minutes) including the 2 hours of the administration of
i.p. chemotherapy (table 2). The median hospitalization
duration in intensive care unity and surgery unity was 3
days (range: 1 to 21 days) and 18 days (range: 12 to 66
days), respectively. The median delay between the surgeryWorld Journal of Surgical Oncology 2009, 7:14 http://www.wjso.com/content/7/1/14
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and the resumption of feeding was 7 days (range: 3 to 28
days). Rehospitalization in the surgery unit was required
for 16 patients (median: once, range: 0 to 3 times), for
restoring bowel continuity (in 7 patients), infection (3
patients), abdominal pain (3 patients), bowel occlusion
(2 patients) and renal failure (1 patients).
Complications and toxicity
The safety analysis reported no severe haematological or
non-haematological toxicity induced by intra operative
i.p. chemotherapy. No patient died due to the complica-
tions of surgery or the i.p. chemotherapy. The most fre-
quent complication was infection, including urinary or
pulmonary infection which occurred in 9 and 3 patients,
respectively (table 3). 13 of 47 patients require a re-
laparotomy (4 patients needed 2 re-laparotomy) and we
exclude from this total the 6 patients who had a surgical
restoration after 30 days. Peritonitis and intra-abdominal
abscess was observed in 5 and 3 patients respectively, they
required a laparotomy to rinse and clean up the peritoneal
cavity. This surgical intervention was also necessary for
intra abdominal bleeding and intestinal necrosis which
occurred in 7 and 2 patients, respectively. Two patients
presented a bowel occlusion which recovered with medi-
Table 1: Characteristics of patients
Characteristics of patients (N = 47)
Median age (years) 59 (Range: 35–75)
GOG Performans status 0 40 (85%)
≥ 1 7 (15%)
Histologic type
Serous adenocarcinoma
Well differentiated 19 (40%)
Moderately/poorly differentiated 20 (43%)
Endometrioid adenocarcinoma 5 (11%)
Mixed epithelial carcinoma 2 (4%)
Clear cell carcinoma 1 (2%)
Visible residual macroscopic disease
Yes 20 (43%)
No 27 (57%)
Induction Chemotherapy (paclitaxel – carboplatin regimen) 31 (66%)
Initial surgery 16 (44%)
Second look surgery 16/16* (100%)
Total number of i.v. cycles of chemotherapy 6 (Range:5–8)
* Surgery during which was performed intra operative i.p. chemotherapy
Table 2: Duration of hospitalization
Median Range
Duration of surgery* (h = hours, mn = minutes) 7 h 10 mn 5 h 10 mn- 9 h 30 mn
Duration of hospitalization in intensive care unity 3 Days 1–21 Days
Duration of hospitalization in surgical unity 18 Days 12–66 Days
Delay between surgery and resumption of feeding 7 Days 3–28 Days
Number of rehospitalization 1** 0–3 times
* including the 2 hours of IIP chemotherapy
** concerning 16 patientsWorld Journal of Surgical Oncology 2009, 7:14 http://www.wjso.com/content/7/1/14
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cal treatment. Thromboembolic events occurred in 5
patients, including a pulmonary embolism in 1 patient. In
5 patients, grade 2 renal failures occurred during the first
10 days after surgery with i.p. cisplatin chemotherapy and
they recovered after i.v. hydration with normal saline 2.2
mM Ca2+ glucuronate, 1 g/l Mg2+, 2 g/l KCl and 3 g/l NaCl.
One patient presented a grade 3 renal failure with uncom-
pleted recovery and which needed stringent follow up. No
grade 4 haematological toxicity was observed. Six patients
presented grade 3 anaemia and 5 patients presented grade
3 neutropenia without fever. Grade 2 thrombopenia
occurred in only one patient. After a 30-day period, com-
plications were surgery related (table 4). Chronic
diarrhea, dysuria and abdominal pain were observed in 9,
8 and 2 patients, respectively. A surgical restoration was
necessary for vesico-vaginal fistula, bowel fistula and
entero-vesical fistula in 3, 2 and 1 patients, respectively.
Efficacy
After a median follow up of 23.3 months, a recurrence of
the disease was observed in ten patients. The median dis-
ease free progression duration was 14.3 months (range:
9.6 – 23.3 months). Sites of relapse were peritoneal carci-
nomatosis in 4 patients, peritoneal nodes in 4 patients,
pleural effusion in 3 patients, liver metastasis in one
patient. At 24 months, the rate of patients alive without
recurrence was 62.5% [95% CI, 55% to 70%] (Figure 1).
No data in term of OS was of value due to the length of
follow-up.
Discussion
Intra-peritoneal administration of chemotherapy is com-
monly performed at a distance from surgery by an i.p.
catheter with artificial ascites [9,24]. Women who have a
successful optimal resection of their cancers with micro-
scopic residual tumour and no bowel resection are the
best candidates for i.p. chemotherapy [25]. It seems favo-
Table 3: Early complication and toxicity by patient including intraoperative toxicity (within 30 days after surgery and i.p. 
chemotherapy)
Type of complication Number of patients % of patients
Post operative pain 10 21.3
Infectious Peritonitis 5 10.6
Intraabdominal abscess 36 . 4
Others infectious complications* 12 25.5
Intraabdominal bleeding 7 14.9
Intestinal necrosis 24 . 3
Bowel occlusion 24 . 3
Thromboembolic events** 5 10.6
Renal failure
Grade 1 6 12.8
Grade 2 5 10.6
Grade 3 12 . 1
Grade 4 00
Anaemia grade 3 5 10.6
Neutropenia grade 3 48 . 5
Febrile Neutropenia 00
Thrombopenia grade 2 12 . 1
* including 9 urinary infection and 3 pulmonary infection
** including: deep venous thrombosis of the leg and the arm in 3 and 1 patients respectively and a pulmonary embolism in 1 patient.World Journal of Surgical Oncology 2009, 7:14 http://www.wjso.com/content/7/1/14
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rable if possible to perform a supra-cervical hysterectomy
and not to enter the vagina because when the vagina is
opened leakage of chemotherapy via the vagina is mostly
risked. However, even if there is no absolute contraindica-
tion to placement of this access device, complications
could occur such as catheter infection or intra-abdominal
abscess, bowel injuries, kinking of the catheter or inflow
obstruction and leakage of chemotherapy around the port
or into the surrounding subcutaneous tissue [24].
Abdominal pain is the most common i.p. chemotherapy-
related risk. In most cases it is due to the distension of the
abdomen but it is very important not to underestimate the
risk of peritonitis or bowel injuries which is a medical and
surgical emergency. Others i.p. chemotherapy complica-
tions included those linked to the drug administered. The
most frequently used drug is cisplatin [26-30]. Nausea,
vomiting and renal toxicity must be prevented by effective
anti-emetics drugs and suitable i.v. hyperhydration con-
sidering the systemic exposure to the agent after i.p. com-
parable to i.v. administration [20]. Since the emergence of
this concept of i.p. administration with chemotherapy
reported by Dedrick et al in 1978 [31], several phase II
studies have confirmed the favorable trends obtained by
these treatments in terms of overall and/or progression –
free survival [32,33]. Comparison between i.p. and i.v.
treatments was undertaken in several randomized phase
III clinical trials [26-28]. Recently, Armstrong et al [28]
reported a highly significantly improvement in progres-
sion-free (24 months versus 18.3 months; p = 0.027) and
overall survival (65.6 months versus 49.7 months; p =
0.017) with i.p. therapy. Because of the need to recover
from surgery, the beginning of the i.p. chemotherapy is
often delayed and performed at distance of surgery. The
Table 4: Complication's later than 30 days since surgery and i.p. 
chemotherapy
Type of complication Number of patients % of patients
Vesico-vaginal fistula 36 . 4
Bowel fistula 24 . 3
Entero-vesical fistula 12 . 1
Chronic diarrhea 91 9 . 1
Chronic dysuria 81 7
Chronic abdominal pain 24 . 3
Loss of weight * 48 . 5
* more than 10% of the weight 3 months after surgery
Disease free survival in intraoperative i.p. chemotherapy group and control group Figure 1
Disease free survival in intraoperative i.p. chemotherapy group and control group.World Journal of Surgical Oncology 2009, 7:14 http://www.wjso.com/content/7/1/14
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occurrence of adhesion barriers will be embarrassing for
an optimal distribution of chemotherapy in the abdomi-
nal cavity. One should consider that the most frequent
sites of recurrences are those where i.p. chemotherapy is
unable to reach. Advocates of adhesion formation barriers
could be used to limit their incidence but efficacy is not
clearly demonstrated in this situation. Relying on these
considerations, i.p. chemotherapy during surgery was sug-
gested with the aim to improve results. The administra-
tion of i.p. chemotherapy during the surgery allows an
optimal peritoneal cavity exposure warranted by the con-
trol of the surgeon who stirs the cisplatin liquid by hand
inside the peritoneal cavity. This method presents the
advantage to not require an i.p. catheter and to provide
optimal diffusion. The aim of our study was to analyze its
feasibility. One of our questions was to determine the
optimal dose of i.p. cisplatin, knowing that standard regi-
men in i.p. clinical trial uses a dose of 50 to 100 mg/m2
cisplatin [24]. A search for optimizing the dose and sched-
ule of intraperitoneal cisplatin was performed, with the
aim to increase the intraperitoneal concentration and to
limit the systemic spread. The addition of epinephrin in
preclinical model have shown to achieve this goal and
warrant further clinical studies [22]. The dose used in the
present study issued from studies performed in 2005
regarding serum and i.p. pharmacokinetics of platin with
intra-operative chemotherapy. This study concluded that
cisplatin administered at the dose of 50 mg/m2 during 2
hours i.p. chemotherapy resulted in an early dramatic
decrease in i.p. drug concentration, below the targeted
threshold for activity within 15 minutes. The author sug-
gested that performing twice 1 hour i.p. cisplatin chemo-
therapy should increase the length of peritoneal exposure
to a local cytotoxic dose [21]. Relying on these results, we
proposed in our study to perform i.p. chemotherapy in 2
consecutive one-hour administrations with cisplatin
given at a dose of 90 mg. The present paper is the first
demonstration of the feasibility for this modality of intra-
operative i.p. chemotherapy. The described modalities of
administration for i.p. chemotherapy enhance the distri-
bution of cisplatin in the peritoneal cavity without induc-
ing severe and non-manageable toxicities. Those results
suggest further randomized clinical studies aimed to
establish its benefit in terms of survival.
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